Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Definiens Expands Management Team to Develop the Clinical Market

Published: Tuesday, October 29, 2013
Last Updated: Tuesday, October 29, 2013
Bookmark and Share
Company announces appointment of Pablo Jordan and Rebecca Berghorn.

Definiens has announced the next step in its strategic roadmap for driving the clinical market for image analysis. Augmenting the earlier hiring of Ralf Huss as Chief Medical Officer, Definiens has added key business team members, Pablo Jordan and Rebecca Berghorn.

“All experts point to image analysis as one of the key drivers for adoption of digital pathology in the clinical lab. With the addition of our clinical business team leaders, we are well positioned to catalyze and shape digital pathology,” commented Definiens CEO, Thomas Heydler.

Pablo Jordan, a veteran in the pathology diagnostics industry, joins as Vice President Business Development Clinical Digital Pathology, bringing over 15 years of experience in diagnostics and personalized medicine.

He was formerly Vice President Companion Diagnostics for bioMérieux, leading the company efforts to develop innovative companion diagnostics solutions. Prior to that, he held several international management roles at Roche and Ventana Medical Systems.

"I am passionate about the potential impact of Definiens' technology for tissue datafication in the discovery and development of diagnostics tests." says Jordan. "I believe we will play a major role in unlocking the tissue side of personalized medicine."

In addition, Definiens announced the appointment of Rebecca Berghorn as Director of Clinical Product Marketing. She will be responsible for leading the Product Management of Definiens' Clinical Digital Pathology business.

Berghorn has an extensive track record in product management in clinical imaging applications, having worked at GE Healthcare and Philips Healthcare in key roles. Most recently she served as the Vice President for Visia Product Management at Mevis Medical Solutions.

Jordan and Berghorn will both be located in Definiens' Munich Headquarters.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics
Big data approach bridges the gap between genomics and personalized medicine.
Saturday, June 28, 2014
Definiens Appoints Chief Marketing Officer, Merrilyn Datta, Ph.D.
Dr. Datta brings a wealth of experience in marketing and her expertise will be critical as Definiens expands its leadership in the life sciences and tissue diagnostics industries.
Tuesday, April 09, 2013
Definiens Establishes Advisory Board
Renowned industry experts to advise Definiens on clinical digital pathology market.
Thursday, March 28, 2013
Definiens Strengthens Leadership with Key Appointment
Former Aperio executive and digital pathology market expert, Dr. Martin Stuart, joins executive team.
Thursday, February 02, 2012
Definiens Image Analysis Technology Improves Accuracy in Scoring Her2/neu in Breast Cancer Biopsies
New multi-dimensional image analysis platform aids diagnosis and treatment of breast cancer.
Wednesday, June 03, 2009
Scientific News
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Scoliosis Linked to Disruptions in Spinal Fluid Flow
A new study in zebrafish suggests that irregular fluid flow through the spinal column brought on by gene mutations is linked to a type of scoliosis that can affect humans during adolescence.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!